Orphan Medical, Inc., a specialty pharmaceutical company, engages in the acquisition, development, and marketing of pharmaceuticals intended to treat sleep disorders, pain, and other central nervous system (CNS) disorders. Its products include Xyrem (sodium oxybate) oral solution for the treatment of cataplexy associated with narcolepsy; Antizol (fomepizole) Injection, which is used as an antidote for suspected or confirmed ethylene glycol and methanol poisonings; Cystadane (betaine anhydrous for oral solution) for treatment of homocystinuria; Antizol-Vet (fomepizole) for the treatment of dogs that have ingested or are suspected of having ingested ethylene glycol. The company’s products under development include Xyrem (sodium oxybate) oral solution for treatment of excessive daytime sleepiness/Narcolepsy; Xyrem (sodium oxybate) oral solution for Fibromyalgia; and Butamben suspension injection) for treatment of cancer pain, which are in various phases of development. Orphan Medical offers its products through its marketing and sales personnel in the United States, and through contracts with companies in foreign markets. Orphan Medical is based in Minnetonka, Minnesota. As of June 27, 2005, Orphan Medical Inc. is a subsidiary of Jazz Pharmaceuticals, Inc.